Silence Therapeutics plc

Silence Therapeutics plc is a biotechnology company focused on developing a new generation of medicines that utilize RNA interference (RNAi). Their proprietary mRNAi GOLD™ platform enables the creation of siRNAs (short interfering RNAs) specifically designed to target and silence disease-associated genes within the liver. This technology holds significant potential for treating various diseases, particularly those with a genetic basis.

Silence's pipeline currently focuses on three key areas: hematology, cardiovascular disease, and rare diseases. Their wholly owned product candidates include zerlasiran (SLN360) for reducing cardiovascular risk associated with high levels of lipoprotein(a), and divesiran (SLN124) for treating rare hematological diseases such as polycythemia vera. In addition to their internal efforts, Silence collaborates with pharmaceutical companies like AstraZeneca and Hansoh Pharma, further expanding their reach and accelerating the development of innovative therapies.

Silence Therapeutics is a biotechnology company dedicated to transforming people's lives by silencing diseases through precision engineered medicines. They leverage the body's natural mechanism of RNA interference (RNAi) to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, focusing on areas of high unmet need in hematology, cardiovascular disease, and rare diseases. Their innovative mRNAi GOLD™ platform enables durable and reversible gene silencing, potentially offering life-changing therapies for patients with limited treatment options.

Silence Therapeutics promotes a vibrant and innovative culture that encourages diversity, creativity, and a start-up mindset. They are a growing, global company passionate about collaborating with partners and advocates to advance life-changing therapies for patients. Their company values are evident in their commitment to patient-centricity, their collaborative approach to partnerships, and their dedication to a diverse and inclusive workforce.

Silence Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace where all employees feel valued, respected, and empowered to contribute their unique perspectives. They believe that diversity strengthens their innovation and creativity, enabling them to better understand and serve the diverse patient communities they aim to reach. Their efforts focus on attracting, developing, and retaining a diverse workforce, promoting a culture of inclusivity, and ensuring fair and equitable opportunities for all employees.